Table 4 Results of 5 questionnaire studies

Weiss, J.

1 19 months living with combination immunotherapy and severe side effects in 36% VS. 9 months living with standard immunotherapy and severe side effects in 15%

70%/30%

45%/55%

0.050

2 12 months living with combination immunotherapy and severe side effects in 36% VS. 11 months living with standard immunotherapy and severe side effects in 15%

15%/85%

17%/83%

NA

3 24 months living with combination immunotherapy and severe side effects in 36% VS. 3 months of pain-free living without tumor therapy with palliative therapy

80%/20%

50%/50%

0.018

4 Agree to a treatment with many side effects at any time and with the very low prospect of prolonging life

60%

30%

NA

5 Prefer to receive the infusions every three weeks rather than every two weeks with the equivalent effect

92%

83%

6 Prefer early palliative therapy to a therapy rich in side effects if there is no prospect of healing

59%

57%

Vaz-Luis, I.

1 Whether 6 months of chemotherapy would be worthwhile for a 1-, 2-, 6-, 9-, 12-, and 24-month survival benefit

1-month: 18%

2-month: 37%

6-month: 86%

9-month: 93%

12-month: 97%

24-month: 97%

1-month: 42%

2-month: 57%

6-month: 79%

9-month: 87%

12-month: 93%

24-month: 96%

NA

Pacchiana, M. V.

1 Whether interested in maintenance therapy, rather than treatment-free

97%

75%

0.003

2 Whether interested in maintenance therapy if improving life expectancy by about 1 Month, 3 Month, 6 Month, 1 Year

1-month: 14%

3-month: 62%

6-month: 89%

1 Year: 100%

1-month: 46%

3-month: 61%

6-month: 76%

1 Year: 88%

1-month: <0.001

3-month: 0.910

6-month: 0.080

1 Year: 0.030

3 Whether interested in maintenance therapy if providing no survival benefit but would result in symptom control

78%

74%

0.630

4 Whether interested in maintenance therapy if providing no survival benefit but would result in radiologic tumor stabilization

38%

62%

0.010

Krammer, R.

1 16 weeks survival with moderate side effects with ipilimumab VS. 8 weeks survival with mild side effects with chemotherapy

83%/17%

56%/44%

NA

2 3 months survival with mild side effects with chemotherapy VS. 3 months survival free of symptoms with palliative care

10%/90%

32%/68%

3 Spending €100.000 for ipilimumab VS. palliative care VS. skin screening VS. primary prevention

3%/21%/10%/66%

4%/4%/46%/46%

Gandhi, S.

1 Minimum overall survival required to continue aromatase inhibitor 5 years

<1%: 0%

1–2%: 45%

2–5%: 37.5%

5–10%: 12.5%

10–15%: 0%

15–20%: 2.5%

>20%: 0%

<1%: 30.1%

1–2%: 14.4%

2–5%: 11.8%

5–10%: 12.4%

10–15%: 3.9%

15–20%: 3.9%

>20%: 17.0%

NA

2 Minimum decrease in risk of cancer recurrence required to continue aromatase inhibitor 5 years

<1%: 0%

1–2%: 2.5%

2–5%: 37.5%

5–10%: 35.0%

10–15%: 12.5%

15–20%: 0%

>20%: 2.5%

<1%: 27.5%

1–2%: 14.4%

2–5%: 13.1%

5–10%: 14.4%

10–15%: 4.6%

15–20%: 5.9%

>20%: 14.4%